Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCHOTT Doubles its Production Capacity for SCHOTT TopPac® Polymer Syringes

Published: Tuesday, April 30, 2013
Last Updated: Monday, April 29, 2013
Bookmark and Share
Company to offer customers a greater degree of flexibility and ensure supply security.

To address the increasing global demand for prefillable polymer syringes, SCHOTT is currently expanding its manufacturing capacity for small size (1 to 10 ml) SCHOTT TopPac® syringes.

A new production line installed at the SCHOTT site in St. Gallen, Switzerland, expanded the existing production capacity by 100% from April onwards.

This enables SCHOTT to offer customers a greater degree of flexibility and ensure supply security.

SCHOTT is a pioneer in establishing the SCHOTT TopPac® product range as ready-to-fill syringes, which are made of Cyclic Olefin Copolymer (COC).

Over the past 15 years, SCHOTT made significant investments to develop and industrialize COC material for pharmaceutical containers for injectable drugs.

COC is an inert material and the SCHOTT TopPac® syringe system is designed to be compatible with a broad range of drugs. The excellent barrier properties of the SCHOTT TopPac® syringe system allow long term storage of drugs even in small syringe sizes.

In addition, SCHOTT TopPac® syringes have a glass-like transparency, and are break resistant and lightweight.

SCHOTT TopPac® syringes are available in the range from 1ml to 50ml with cross linked silicone for optimal functionality.

Pharmaceutical companies benefit from the fact that SCHOTT TopPac® syringes are manufactured in clean rooms with a fully automated process starting from injection-molding to the final packaging in nest and tub. The syringes are sterilized and are ready for aseptic filling operations.

SCHOTT intends to achieve further growth in the field of polymer and glass syringes and also underscores its commitment to offer ideal product solutions to pharmaceutical companies - today and tomorrow.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCHOTT Announces Major Expansion of Pharmaceutical Packaging Manufacturing in Russia
Capacity to expand by more than 50 percent / Consistent investment strategy helps customers achieve growth and quality objectives.
Monday, November 26, 2012
Scientific News
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!